SI

Shoulder Innovations

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical Devices

Exchange

NYSE

County of HQ

United States

Next Earnings Date

07/24/26

Business Summary

SI operates in the orthopedic medical device space, focusing on shoulder replacement systems sold to hospitals and ambulatory surgical centers. Revenue is generated through the sale of implant systems and associated surgical instrumentation, creating recurring procedure-driven demand as adoption grows. The moat in this segment typically hinges on surgeon relationships, clinical outcomes, and proprietary implant design that integrates into established surgical workflows. If the company can embed its systems deeply within surgeon preference and hospital procurement channels, it can generate durable procedural revenue streams despite current profitability challenges.

 


Analyze SI on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$308

Forward P/E

-

PEG

-

PRICE TO SALES

2.7

PRICE TO BOOK

2.2

EV / EBITDA

-5.4

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$4.65

Next Year EPS Growth Estimate

-$1.47

Next Year Revenue Growth Estimate

31.30%

Return on Equity (ROE)

-28.70%

FREE CASH FLOW

Operating Margin

-55.60%

Debt-to-Equity

0.1

Piotroski F-Score

-

Altman Z-Score

6.3

Return on Invested Capital (ROIC)

-69.60%

Current Ratio

11.1

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze SI on TradingView

Gainseekers Quantitative Analysis

Summary

At a $308M market cap, SI is a speculative, balance-sheet-safe but operationally broken medical device name. The absence of a Forward P/E combined with an EPS of -5.4 and expected EPS of -4.65 tells you this is a company with no earnings visibility, so valuation rests entirely on future execution rather than fundamentals. However, the Altman Z-Score of 6.3 and a Current Ratio of 11.1 indicate minimal near-term bankruptcy risk despite deeply negative Operating Margin of -28.70% and ROIC of -69.60%. The market is not mispricing profitability—it is correctly discounting it—but it may be underappreciating the fortress liquidity profile relative to the small $308M valuation.

AI Exposure / Tech Reliance

As a Medical Devices company in Healthcare, SI operates in a segment where AI-driven surgical planning, robotic assistance, and data analytics are increasingly embedded into product ecosystems. Companies that integrate digital surgical workflows and data-backed outcomes into implant systems can build switching costs with surgeons and hospitals. The ability to align device innovation with AI-enhanced procedural efficiency will determine whether SI remains niche or becomes systemically embedded in operating rooms.

The Bull Case

A value-oriented investor could argue that the balance sheet strength is the hidden asset here: a Current Ratio of 11.1 and an Altman Z-Score of 6.3 suggest substantial financial resilience relative to its size. Despite an ugly Operating Margin of -28.70%, the company is still commanding a Price/Sales of 2.7 and Price/Book of 2.2, which are not extreme for a growth-stage med-tech platform. Return on Equity of 31.30% stands out numerically, implying that equity capital is being leveraged in a way that could amplify upside if margins inflect. With a modest $308M market cap, even incremental operating leverage could materially re-rate the equity if losses narrow toward the estimated EPS of -4.65 next year.

The Bear Case

This is a cash-burning operation with EPS of -5.4, negative ROIC of -69.60%, and a deeply negative Operating Margin of -28.70%, which signals a structurally unprofitable model at present scale. Sales Growth Next Year of -$1.47 indicates contraction rather than expansion, undermining any GARP narrative. The lack of Forward P/E, PEG Forward, Short % of Float, Consensus Rating, and Piotroski F-Score removes critical visibility into quality and sentiment, increasing uncertainty. Debt/Equity of -55.60% adds balance sheet complexity, and without earnings, the 2.7 Price/Sales multiple could compress quickly if growth stalls further.

Market Sentiment & Smart Money

Short Interest %

-

Analyst Consensus

1.4

Average Analyst Price Target

$20.50

Institutional Ownership %

-

1-Year Beta

0.7

Insider Buying % (6 Mo)

-%

Distance to 52-Week High

83.40%

Distance to 52-Week Low

137.00%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.